Biogen Pharmachem Industries Limited (531752) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Biogen Pharmachem Industries Limited stock ₹0.20, price ₹0.29, that is 32.6% below the price, quality 38 out of 100. Rating: overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Biogen Pharmachem Industries Limited
531752 · BSEExpensive (fair value 33% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range ₹0.2229 – ₹1.56 · fair‑value band ₹0.1615 – ₹0.2295 · the ₹0.2900 price screens above the ₹0.1955 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Biogen Pharmachem Industries is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Sun Techno Overseas Limited does not have significant operations. Previously it was engaged in trading shares, mutual funds, and other investments. The company was formerly known as Wellworth Overseas Limited and changed its name to Sun Techno Overseas Limited in August 2011.
Show moreShow less
Sun Techno Overseas Limited was incorporated in 1995 and is based in Rajkot, India.
Stock analysis
Biogen Pharmachem Industries Limited (531752) currently trades at ₹0.2900, while our model-based Fair Value estimate is ₹0.1955, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of ₹0.5300 per share, and 4 of the 15 models we run sit above the ₹0.2900 price.
Bear case: the Earnings-Based group reads lowest at ₹0.1250, and 11 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹0.1615 (bear) to ₹0.2295 (bull), the price of ₹0.2900 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Health Care sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Biogen Pharmachem Industries Limited reported revenue of ₹0 in FY2026 versus ₹21.6M in FY2022. Reported net income was ₹9.6M in FY2026.
Key figures
Market cap ₹305M (≈ $3.3M) Micro · EPS (TTM) ₹−0.0018 · Return on assets (EBIT) 0.9% (5-year average) · Free cash flow ₹15.7M · Net debt ₹534K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).
What moves the price
The share trades about 57% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −35% fair-value upside, at −33%, 531752 screens cheaper than that median.
Fair Value models
All 15 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
531752 screens overvalued: fair value 33% below the price. Compare with ST Pharm Co →
Compare Biogen Pharmachem Industries Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 58 stocks
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on equity by industry
- Quality Score by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Huons Global Co 084110 | 18,970 KRW | 47,019 KRW | +148% | vs 531752 |
| DongKook Pharmaceutical Co 086450 | 24,800 KRW | 28,372 KRW | +14% | vs 531752 |
| ST Pharm Co 237690 | 71,000 KRW | 61,182 KRW | −14% | vs 531752 |
| Vivozon Pharmaceutical Co 082800 | 2,780 KRW | 2,179 KRW | −22% | vs 531752 |
| Oscotec Inc 039200 | 32,750 KRW | 21,262 KRW | −35% | vs 531752 |
| NatureCell Co 007390 | 21,800 KRW | 11,176 KRW | −49% | vs 531752 |
| Mezzion Pharma Co 140410 | 63,800 KRW | 31,450 KRW | −51% | vs 531752 |
| BINEX Co 053030 | 6,800 KRW | 1,844 KRW | −73% | vs 531752 |
| Caregen Co 214370 | 26,850 KRW | 5,414 KRW | −80% | vs 531752 |
| SHUKRAPHAR SHUKRAPHAR | ₹82.25 | ₹9.14 | −89% | vs 531752 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Biogen Pharmachem Industries Limited (531752) overvalued or undervalued?
What is the fair value of 531752?
What is the quality score of 531752?
What is the price target for Biogen Pharmachem Industries Limited (531752)?
What is the Biogen Pharmachem Industries Limited stock forecast for 2026?
What growth is priced into Biogen Pharmachem Industries Limited (531752)?
What discount rate (WACC) does the fair value of 531752 use?
What is a reverse DCF?
How much growth has Biogen Pharmachem Industries Limited (531752) delivered so far?
How fast is the sector of Biogen Pharmachem Industries Limited (531752) growing?
What is the free cash flow yield of Biogen Pharmachem Industries Limited (531752)?
What is the intrinsic value of Biogen Pharmachem Industries Limited (531752)?
Is Biogen Pharmachem Industries Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 531752?
How much is Biogen Pharmachem Industries Limited worth?
What do the bullish and bearish scenarios say about 531752?
How far is 531752 from its 52-week high?
Which stocks are comparable to Biogen Pharmachem Industries Limited?
Is Biogen Pharmachem Industries Limited stock attractive at the current price?
How is the fair value of 531752 calculated?
Is it still worth investing in stocks now?
What is the share price of Biogen Pharmachem Industries Limited (531752)?
What should I pay attention to with Biogen Pharmachem Industries Limited right now?
Key figures of Biogen Pharmachem Industries Limited
How large is the market capitalisation of Biogen Pharmachem Industries Limited (531752)?
What are the earnings per share of Biogen Pharmachem Industries Limited (531752)?
What is the EBIT return on assets of Biogen Pharmachem Industries Limited (531752)?
How much net debt does Biogen Pharmachem Industries Limited (531752) carry?
Watch Biogen Pharmachem Industries Limited in the live analysis
One click puts Biogen Pharmachem Industries Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.